INNOCARE (09969) saw its shares rise more than 4% during the morning trading session. As of the time of writing, the stock was up 3.95%, trading at HK$11.83, with a turnover of HK$38.70 million. The company previously issued a performance forecast, anticipating revenue of RMB 2.37 billion for 2025, representing a year-on-year increase of approximately 134%. It is also projected to achieve its first-ever net profit attributable to shareholders in 2025, reaching around RMB 630 million. The core product, Orelabrutinib, contributed significantly to this growth. Furthermore, the approval and market launch of Tafasitamab in May 2025 further diversified the company's drug revenue streams. Two business development transactions completed during the year also served as another crucial factor driving the rapid revenue growth in 2025. Notably, INNOCARE announced that patient enrollment has been completed for the Phase III clinical trial of its self-developed novel TYK2 inhibitor, ICP-488, for the treatment of psoriasis. A total of 383 patients were enrolled. This milestone signifies a major clinical advancement for ICP-488 in treating psoriasis, potentially offering a new oral treatment option for patients. This multicenter, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of ICP-488 as a monotherapy for adult patients with moderate to severe plaque psoriasis.